Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GHRS with free AI briefings, catalyst countdowns, and dilution alerts.

GHRS · GH Research PLC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$362.6M Cash on Hand
84.2mo Cash Runway
Follow GHRS by email Get an email when GHRS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GHRS, unsubscribe in one click. Privacy

📣 What GHRS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
5 Methoxy N,N Dimethyltryptamine Treatment Resistant Depression Phase 1/2 · NCT04698603 Completed
Mebufotenin Treatment-resistant Depression Phase 2 · NCT05800860 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GHRS holds $362.6M in cash and short-term investments and burns about $12.9M/quarter from operations, an estimated runway of 84.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 22 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GHRS files for a raise →

👥 Who Owns GHRS

Insiders 24.2% Other 5%+ holders 21.4% Institutions (103 holders) 54.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
Florian Schonharting
Director · +2,303 options
Insider 14,824,419 23.90% 2026-04-01
Lynx1 Capital Management LP 5%+ holder (13G) 13,263,288 21.38% 2026-06-30
BVF PARTNERS L P/IL Institution (13G, 5%+) 8,650,158 13.95% 2026-09-30
FMR LLC Institution (13G, 5%+) 6,482,945 10.45% 2026-09-30
RA Capital Management, L.P. Institution (13G, 5%+) 3,609,007 5.82% 2026-09-30
Magnus Clemensen Halle
Managing Director, Ireland
Insider 118,354 0.19% 2026-03-18
Michael Forer
Director · +100,000 options
Insider 45,509 0.07% 2026-03-18
Duncan Moore
Director · +2,202 options
Insider 14,600 0.02% 2026-03-18
Dermot John Hanley
Director · +2,202 options
Insider 2,432 0.00% 2026-03-18

Share count 62,029,395 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full GHRS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GHRS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.